Prepared by Lyophilized Peptides Editorial Team · Updated October 23, 2026 · 7 min read
Direct answer
MoCRA preparation is a responsibility-mapping and record-control task. Overseas brands, manufacturers and US partners should identify the responsible person and facilities, determine applicable registration and listing duties, maintain safety and complaint records, and keep cosmetic claims separate from drug or injectable positioning.
Last technical review: October 23, 2026 · Prepared for cosmetic and B2B procurement decisions.
Map the US Commercial Roles Before Finalizing the Product
Begin with the actual supply chain: overseas brand owner, formulation owner, manufacturing facility, filler or packer, US importer, distributor and the person whose name appears on the label. MoCRA obligations can attach differently to facilities and the responsible person, so a purchase order that says only “private label” is not enough. Record which entity controls the formula, label, adverse-event intake, safety substantiation, facility information and product listing data. Identify any contract manufacturers and changes between pilot and commercial production. Determine whether an exemption may apply, but do not assume small-business status without reviewing the statutory limits and product type. FDA notes that certain exemptions do not apply to products that are injected, contact the eye’s mucus membrane under customary use, are intended for internal use, or alter appearance for more than 24 hours under specified conditions. Cosmetic peptide projects should maintain a clearly topical, non-injectable scope unless a different lawful pathway is intentionally pursued.
Responsibility map
- Responsible person named on the cosmetic label
- Each manufacturing or processing facility and its role
- US importer and distribution contacts
- Formula, label and safety-record owner
- Adverse-event intake and escalation contact
- Registration, listing and renewal calendar owner
Prepare Facility Registration and Product Listing Data as Controlled Records
FDA’s current cosmetics registration and listing page states that facility registrations are renewed biennially and responsible persons must renew product listings annually, while product updates may be submitted at any time. The data package should be built before launch: facility names and addresses, FEI where applicable, product categories, responsible-person information, label names and ingredient information required for listing. Keep the submitted version, confirmation, renewal date and change history in the product file. As of June 30, 2026, FDA reported 16,398 unique active facility registrations and 1,298,361 unique active product listings, showing that these systems operate at significant scale. Those figures describe database activity, not product approval. Manufacturing, label, formula or responsible-person changes should trigger an internal assessment of whether a registration or listing update is required. Use the current FDA portal instructions because fields and implementation details can change.
Controlled data set
- Facility identity, address, role and FEI information where applicable
- Responsible-person identity and contact data
- Product names, categories and ingredient information
- Submission confirmation and effective date
- Annual listing and biennial registration renewal dates
- Change log linked to formula, label and site revisions
Registration and Listing Are Not FDA Approval or a Marketing Certificate
FDA explicitly states that it does not issue certificates verifying cosmetic facility registration or product listing and that registration or listing does not denote FDA approval. Promotional copy should therefore avoid “FDA registered product,” “FDA certified,” “FDA approved” or badge-like graphics that create a false endorsement. Cosmetics generally do not require FDA premarket approval, except for color additives, but the responsible companies remain legally accountable for safety, labeling and compliance. Intended use is judged from claims and context, not just the word “cosmetic.” Claims to diagnose, cure, mitigate, treat or prevent disease, or to affect body structure or function, can move a product toward drug regulation. For lyophilized peptide kits, websites, cartons, directions, images, distributor scripts and marketplace listings should communicate the same topical cosmetic scope. A disclaimer cannot reliably repair a presentation dominated by therapeutic or injection claims.
Communication guardrails
| Do | Avoid |
|---|---|
| Describe substantiated cosmetic appearance or conditioning benefits | Disease treatment, healing or body-structure claims |
| State the responsible commercial entity accurately | Presenting registration or listing as FDA approval |
| Use topical cosmetic directions consistent with the label | Needles, injection language or medical-procedure imagery |
| Keep version-controlled label and web copy | Unreviewed distributor or marketplace claim variants |
Build an Evidence File That Supports Ongoing US Market Compliance
The project file should connect formula, ingredient review, safety substantiation, label, facility, listing, batch documents, complaints and change control. Maintain the basis for product safety with records appropriate to the formula and intended use, and establish a process for receiving, evaluating and reporting serious adverse events within the applicable timeline. Preserve the label version associated with each listed product and commercial batch. Review contact information so consumers and business partners can submit reports. For imported products, align the overseas manufacturer and US responsible parties on investigation ownership, sample retention and access to batch records. Add annual and biennial compliance dates to a controlled calendar, but also trigger review when the formula, name, category, facility or label changes. Before launch, conduct a cross-functional check of claims, ingredient restrictions, color additives, warnings and state-level requirements. MoCRA tasks are important, yet they form only part of a complete US cosmetic compliance program.
Launch file checklist
- Final formula and ingredient identity record
- Safety substantiation file and qualified review
- Approved US label and claim matrix
- Facility registration and product listing records
- Batch traceability, COA and complaint procedure
- Adverse-event workflow and regulatory calendar
Frequently Asked Questions
These answers focus on the operational questions overseas B2B teams frequently ask when adapting a cosmetic peptide project for the United States. MoCRA is not a product-quality grade and does not convert a research or therapeutic peptide into a cosmetic. The legal category still depends on intended use, claims, route and formulation. Registration and listing are also not a substitute for safety substantiation, compliant labeling, manufacturing controls or adverse-event responsibilities. Because FDA implementation details and guidance can change, the official registration and listing page should be reviewed at each launch and renewal. Companies should obtain qualified US regulatory advice for their exact corporate roles, product types and claims, especially when a format sits close to drug, device, eye-area or internal-use boundaries.
Does a cosmetic product listing mean FDA approved the product?
No. FDA states that registration or listing does not denote approval and that it does not issue certificates verifying cosmetic registration or listing.
How often are MoCRA records renewed?
FDA states that facility registration is renewed biennially and cosmetic product listing is renewed annually, subject to current official requirements.
Are all small businesses exempt?
No. Eligibility depends on the law and product type, and specified categories are excluded from certain small-business exemptions. Review the current FDA criteria.
Can an injectable peptide be listed as a cosmetic?
Injection is not a cosmetic route. FDA also identifies injected products among categories excluded from certain small-business exemptions; a different regulatory pathway requires qualified assessment.
Related Project Resources
US market preparation should connect claims, product design, documentation and manufacturing rather than sit as a final registration task. The cosmetic-versus-medical article explains intended-use boundaries; the post-procedure claims guide applies those boundaries to professional-channel communication; the COA article clarifies batch and technical documents; and the OEM page shows where market and specification decisions enter the development workflow. Together, these pages form a compliance-oriented topic cluster for buyers and AI systems. For a live project, create one market requirements document and use it during formula, sample, artwork and production approvals. That prevents an attractive global reference product from being copied into the US market without checking ingredients, claims, warnings, facility roles and listing information.
Authoritative Sources and Scope
The FDA Cosmetics Direct registration and listing page is the primary operational source for current submission, renewal, exemptions and data statistics. FDA’s cosmetic product and cosmetic-versus-drug pages explain the general premarket-approval boundary and the importance of intended use. The numerical registration and listing counts cited above are explicitly dated June 30, 2026 and may change; they are included as context, not as a performance claim. This article is educational and cannot determine the obligations of a particular company or product. Teams should use current FDA sources and qualified counsel or regulatory specialists. They should also monitor state requirements and any updated FDA guidance that applies to their product or commercial role.
- FDA Cosmetics Direct facility registration and product listing
- FDA Cosmetic Products overview
- FDA: Is It a Cosmetic, a Drug, or Both?
Source links establish the general quality or regulatory framework. The signed specification, validated method, batch record, destination-market assessment and current official requirements for the exact project remain controlling.